Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions.
about
Drugs derived from phage display: from candidate identification to clinical practiceThermostable llama single domain antibodies for detection of botulinum A neurotoxin complexStability engineering of scFvs for the development of bispecific and multivalent antibodies.Identification of an antibody fragment specific for androgen-dependent prostate cancer cells.Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies.Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.Evaluation of antidiphtheria toxin nanobodies.The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.Molecular engineering of antibodies for therapeutic and diagnostic purposes.Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion.Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs.Advancing the immunoaffinity platform AFFIRM to targeted measurements of proteins in serum in the pg/ml range.Enhanced stabilization of a stable single domain antibody for SEB toxin by random mutagenesis and stringent selection.
P2860
Q27007101-8D050E97-2813-4279-A67C-0D1FF00BBA79Q33378940-ED551628-B7CC-4F51-BB51-9F4EEEDB0394Q33574335-F31B517C-15CA-4AC1-B67C-971BFB0FA4DEQ34152258-6CF924F6-2395-4BA5-B993-A57FE60BB50DQ36130672-F9672D9C-BF7D-472D-AC5F-FAE5F6A50E50Q36761690-6907BAD4-3E69-41FD-918A-92C7F048FA71Q37194095-B8ED4FCA-20EE-4EE9-94E5-691ED1C32DDBQ37717652-A014767D-E0E4-4B2E-B901-BF5A91A2659CQ38017581-9D939C23-FCB1-46BA-B865-FE0B552DD0AAQ39753915-A7D87645-2ADD-4BA4-85AB-C0368931F902Q47584726-F0819D05-B89A-4D02-886A-8617B190F209Q47831558-B5E0D8FE-5BF7-4EA0-989C-BD9AFC8A62A8Q50041836-07F43B46-700E-4CC3-8B0E-16EEFEA5F578Q53627592-99AAB499-8A2A-4E36-954F-CE6D2FF1F898
P2860
Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Selecting for antibody scFv fr ...... ion under reducing conditions.
@ast
Selecting for antibody scFv fr ...... ion under reducing conditions.
@en
type
label
Selecting for antibody scFv fr ...... ion under reducing conditions.
@ast
Selecting for antibody scFv fr ...... ion under reducing conditions.
@en
prefLabel
Selecting for antibody scFv fr ...... ion under reducing conditions.
@ast
Selecting for antibody scFv fr ...... ion under reducing conditions.
@en
P2093
P1476
Selecting for antibody scFv fr ...... ion under reducing conditions.
@en
P2093
Eeva-Christine Brockmann
Markus Vehniäinen
Matthew Cooper
Nelli Strömsten
Petri Saviranta
P304
P356
10.1016/J.JIM.2004.11.008
P577
2004-12-02T00:00:00Z